Inhibrx announced first win data for its OX40 agonist immunotherapy in head and neck cancer, reporting responses that were most striking in a subset of patients with HPV-positive tumors. The company framed the result as a meaningful signal for a target that has seen repeated failures across the class. The company’s mid-stage update is positioned as opening combination opportunities, including with cancer vaccines in tumors with lower immunogenicity. OX40 agonism has been a recurring clinical strategy in immuno-oncology, but the latest data could clarify whether biomarker-selected populations benefit. Inhibrx’s CEO Mark Lappe highlighted the clinical durability of the approach as the company moves toward broader development planning. For investors and partners, the key question will be whether this early signal translates into confirmatory improvements in response rate and durability in larger, biomarker-stratified cohorts.